Twenty years of sky-high tuberculosis (TB) incidence rates and high TB mortality in high human immunodeficiency virus (HIV) prevalence countries have so far not been matched by the same magnitude or breadth of responses as seen in malaria or HIV programmes. Instead, recommendations have been narrowly focused on people presenting to health facilities for investigation of TB symptoms, or for HIV testing and care. However, despite the recent major investment and scale-up of TB and HIV services, undiagnosed TB remains highly prevalent at community level, implying that diagnosis of TB remains slow and incomplete. This maintains high transmission rates and exposes people living with HIV to high rates of morbidity and mortality.
fatal cases undiagnosed in life. 4, 5 Of the estimated 430 000 TB-related deaths among PLHIV during 2011, 79% were in Africa. These stark facts demonstrate the urgent need to strengthen TB prevention and care services using all available approaches, including more ambitious TB screening strategies.
TB screening is the fi rst step in both anti-tuberculosis treatment and TB prevention pathways, and has an integral place in routine HIV care and infection control. Key potential entry points for TB screening are illustrated in Figure 1 . TB screening can be conducted at the clinic, facility or community level (Table 1), [6] [7] [8] [9] [10] [11] [12] and can be initiated by TB programmes, infection control services in general facilities or HIV testing and care services. Developing and scaling up effective TB screening strategies will ideally follow the same kind of combined approach that has proved effective for HIV testing and counselling (HTC). Diagnostic testing, provider-initiated HTC and promotion of client-initiated testing through 'know your status' campaigns in facility-and community-based testing services have led to remarkable progress in universal access to HIV testing and care, with both HIV and TB incidence rates falling regionally. 13 Early HIV detection and antiretroviral therapy (ART) are increasingly being recognised as critical for HIV prevention. Recommendations in the United States are moving towards annual HIV screening for all adults, while in Africa increasing emphasis is placed on home-based testing, due to much higher acceptability and uptake than other modalities. 14 These ambitious targets and achievements contrast with a more conservative approach to TB screening. Although TB, like HIV, has characteristically prolonged infectiousness before diagnosis that plays a critical role in maintaining transmission in the community, there is no TB equivalent of the rapid diagnostic tests for HIV that provides highly sensitive and specifi c results within 20 minutes and cost less than US$1. New diagnostics for TB, increasing levels of political commitment to reducing HIV-related TB morbidity and mortality, and the optimism arising from the success of ART scale-up has heightened interest in TB screening, including 'active' and 'intensifi ed' case-fi nding approaches in communities.
Figure 1
Patient flow and main entry points into TB screening. HIV entry points (5 and 6) are considered separately from other targeted risk groups, such as household contacts (4) . TB screening can be directed against subclinical TB or at early stages of health seeking. TB = tuberculosis; HIV = human immunodeficiency virus; HCW = health care worker.
SCREENING FOR TB AS PART OF THE RESPONSE TO TB-HIV IN HIGH HIV PREVALENCE SETTINGS

International policy
International policy is supporting more intensive use of TB screening, with updated recommendations for screening in PLHIV and close contacts of TB patients published by the World Health Organization (WHO) in 2012 and guidance encouraging broader consideration of screening in other priority groups, as well as operational research priorities. [15] [16] [17] More defi nitive TB screening guidelines will be published in 2013 following systematic reviews that have highlighted major evidence gaps but which also stress the need for caution.
Rationale and general principles
The main aims of TB screening are 1) to reduce individual morbidity and mortality through early diag-nosis and treatment, 2) to reduce TB transmission by shortening the infectious period ( Figure 2 ) and 3) to exclude TB to allow preventive treatment (such as isoniazid) to be started. In PLHIV, screening also reduces the risk of severe 'unmasking' of infl ammatory reconstitution infl ammatory syndrome (IRIS) when starting ART, 17, 18 and may reduce early mortality in the critical ill. TB screening serves to raise awareness of TB symptoms and can have an important 'indirect' effect on subsequent health seeking, reducing subsequent patient delays in health seeking as well as providing direct access to diagnosis. This is especially pronounced in community-based interventions, and may have been a major contributor to the success of two recent interventions that reduced undiagnosed infectious TB at the population level. 6, 7 Finally, TB screening has clear opportunities for linkage with HIV testing and care services, as discussed below. 
Epidemiology of undiagnosed tuberculosis disease
The target of TB screening is undiagnosed infectious TB, which is still highly prevalent, as summarised in Table 2 . 7, 9, 10, 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Variation between countries is marked and predates the HIV epidemic. 1, 32, 33 Lengthy delays in diagnosis and missed diagnosis are still r eported by many HIV-positive and HIV-negative TB patients, despite major investment in strengthening health systems and TB services during the last decade. 17, 18, 34, 35 Patient delays in seeking care can also be prolonged, particularly among HIV-negative TB patients, for whom recent estimates suggest a mean duration of smear positivity before diagnosis of >1 year in A frica and even longer in many parts of Asia. In contrast, HIV-related TB progresses more rapidly, with a relatively brief duration of infectiousness (mean of a few weeks to months). 20, 25, 26 A substantial percentage of the total burden of undiagnosed smearpositive TB in the general community, the main driver of TB transmission, is thus HIV-negative individuals, even in very high HIV prevalence settings ( Table 2 and Figure 3 36 ). HIV-related TB, however, dominates the epidemiology of undiagnosed disease in facilities ( Table 2) .
Undiagnosed infectious TB in HIV-negative individuals is an important control target because of its disproportionate contribution to community transmission, and also due to the high responsiveness to interventions. For example, in Zimbabwe, the prevalence of culture-positive TB fell by 61% in HIVn egative individuals but only 25% in HIV-positive individuals (overall decline 41%) during a 2.5 year intervention based on 6-monthly periodic TB screening in the community targeting individuals with chronic cough and using smear microscopy for diagnosis. 7 By the end of the intervention, most undiagnosed infectious TB was HIV-related ( Table 2 : study 5), illustrating the need for combined approaches to prevent prolonged transmission from HIV-negative patients and reducing the high incidence of new TB disease among PLWHA. 7 Whom to target? Subgroups in whom undiagnosed TB prevalence is consistently ⩾1% (number needed to screen [NNTS] of <100 to detect one case of TB if using perfect screening tools), and people being considered for isoniazid preventive therapy (IPT) are the natural focus of screening efforts. 16 These include patients attending HTC clinics or HIV care clinics, 18,37-39 unselected medical admissions and out-patient attendees, 9, 38 household contacts of TB patients, 21, 40 prisoners, 38 silica-exposed mineworkers, 10 unselected adults in some communities, 12, 19, [21] [22] [23] 26 and adult residents volunteering symptoms of TB during surveys or outreach TB screening. Prevalence in adults in the general community and other risk groups, including diabetics, is highly variable and needs local situational analysis to guide planning. 7, 34, [41] [42] [43] Household contacts, PLHIV and facility attendees stand out as having much higher prevalence rates than other risk groups ( Table 2 and 38 ), indicating an urgent need for effective TB screening using accurate diagnostic tools to provide individual benefi t. However, undiagnosed TB in these subgroups is more of a symptom than the main contributor to TB transmission in communities. 35, 44 
OPTIMAL SCREENING STRATEGIES FOR DIFFERENT PRIORITY GROUPS
TB screening has a number of different goals and entry points (Figures 1 and 2) affecting where, how and how often screening should be carried out. For instance, prevention of mortality is the overriding goal when screening acutely ill in-patients, and ideally requires diagnostics able to rapidly detect disseminated HIV-related TB (Figure 2 ). At the other extreme, interventions aimed at reducing transmission in the general community need to detect infectious participants affordably and effi ciently ( Figure 2 ). Critical decisions include which algorithm to use, and whether or not to screen for subclinical TB. Following the general principals of screening, sensitive screening tests should be confi rmed by a highly specifi c test. 45 As no current TB screening algorithm is ideal, compromises have to be made. 46, 47 In practice, TB screening usually starts with either symptoms or X-ray, 48 although there is increasing use of Xpert ® MTB/RIF (Cepheid, Sunnyvale, CA, USA) as both initial and confi rmatory test. 9, [49] [50] [51] The performance of all tests tends to be less good due to lower sensitivity when used for screening than for patient-initiated diagnostic testing, as the spectrum of undiagnosed disease detected is shifted towards earlier, paucibacillary cases (Figures 2 and 3): this includes culture, smear microscopy and Xpert. 30, 41, 49, 50, [52] [53] [54] There is considerable incremental yield from combining different tests, or repeating the same test on different specimens. 30, 53, 55 All tests also have relatively low positive predictive value when used for screening, due to the lower prevalence of true disease.
Symptom screening TB symptoms are the most common fi rst step in TB screening, and may currently be the only feasible option in many settings. However, undiagnosed TB can occur without any reported TB symptoms and, irrespective of HIV status, less than half of culturepositive participants have the 'hallmark' symptom of prolonged cough. 18 In a meta-analysis of data from 8148 PLHIV screened using culture, prolonged cough was reported by 1530 (20.0%) participants and identifi ed 260 (52.5%) culture-positive participants, while one or more of the four symptoms (cough, fever, night sweats or weight loss) was reported by 3563 (46.6%) participants, including 418 (84.4%) with confi rmed TB. 18 
Subclinical tuberculosis
Subclinical TB (culture-positive TB with none of the above four symptoms) is consistently identifi ed whenever screening is carried out. In very high transmission settings, including household contacts and newly diagnosed patients attending HIV care clinics, numbers of patients with subclinical culture-positive disease can exceed symptomatic cases, and reach very high rates (up to 15%). 18, 31, 50, 56 However, the consequences of missing subclinical TB disease need to be weighed against the expense and consequences of more systematic screening of all suspects. For example, adding extra steps in an already tortuous patient pathway could increase loss to care.
Individual consequences of missing subclinical active TB include IRIS, which is rarely fatal, although extremely unpleasant and disruptive to HIV care. 57, 58 Inappropriate isoniazid monotherapy may even be lifesaving in HIV-positive patients with diffi cult-todiagnose TB, 59 and there is no clear evidence of increasing drug resistance. 60, 61 The extent to which subclinical TB contributes to overall TB transmission is unclear, 36 and will depend on how infectiousness relates to symptoms ( Figure 3 ). Local TB epidemiology can be dominated by stable, minimally symptomatic but highly infectious 'super-spreaders', 62 but this does not appear to be a common phenotype, 26 and pronounced reductions in undiagnosed TB at the population level can be achieved without systematic screening for subclinical TB. 7, 11, 12 Radiological screening Chest radiography (CXR) provides the opportunity for high-volume TB screening, and is increasingly feasible due to digital technology. Computer-aided diagnostics, 63 validated reading and scoring systems, 64 remote reading and lay readers 65, 66 are all under active investigation. CXR is already part of the adult and paediatric TB diagnostic algorithms, and combines high sensitivity with reasonably high specifi city. 65, 67, 68 Immediate decisions on the need for confi rmatory testing and follow-up can be made by trained readers, 64, 66 as exemplifi ed by outreach interventions among hard-to-reach risk groups in Europe. 65, 69 HIV immunosuppression affects radiological manifestations of TB; low sensitivity has been reported in clinicbased screening, 30, 70 but not in community-based studies. 48 Two studies from Botswana reported a lowto-modest yield and high incremental cost of adding CXR to clinic-based symptom screening. [71] [72] [73] The main barriers to use are the high capital costs, radiation hazard and lack of skill base in Africa.
New tuberculosis diagnostics for tuberculosis screening
Xpert and urinary lipoarabamannan (LAM) antigen detection are both new diagnostics being used for TB screening, mainly in the context of HIV care. The de-velopment and roll-out of the Xpert platform is a major breakthrough for the diagnosis and management of HIV-related TB and multidrug-resistant TB (MDR-TB) that was endorsed by the WHO in 2010. 74 It has increased sensitivity compared to smear microscopy, and has led to a clinically important decrease in time to diagnosis and treatment initiation in self-presenting patients with suspected TB. The sensitivity of Xpert compared to culture is highest in hospital in-patients with TB symptoms (82-91%). 75 Data on the use of Xpert as a TB screening tool in high HIV prevalence populations are currently limited to four studies (Table 3) ; 9,49-51 however, these numbers are likely to increase rapidly. Excluding one very small study of fi ve culture-positive cases, the sensitivity of Xpert compared to culture was lower when used for diagnostic testing (range 58.3-88.2%), but much more sensitive than smear microscopy (sensitivity range 17.6-52.8%). Use of Xpert for routine diagnostic testing is likely to be cost-effective in many settings; 76, 77 however, affordability, limited throughput capacity and substantially lower sensitivity than culture and CXR may restrict the widespread adoption of this test for screening to specifi ed high TB prevalence groups, such as PLHIV, facility attendees and close contacts, and to confi rmatory testing after CXR or symptom screen. More research is needed to defi ne sensitivity, specifi city and feasibility in these groups.
LAM is a Mycobacterium tuberculosis cell-wall polysaccharide that can be detected in the urine of TB patients, and is now available as a point-of-care lateral flow assay. 29 It is a useful screening test in PLHIV with advanced immunosuppression, diagnosing disseminated disease that tends to smearnegative. Its low sensitivity and suboptimal specificity limit the value of the test in patients with CD4 count of >200 cells/mm. 29 LAM has marked prognostic signifi cance predictive of high mortality, and a number of clinical trials are ongoing in South Africa and Uganda.
MANAGEMENT OF HIV AND TUBERCULOSIS IN SCREENING PARTICIPANTS
Integrating TB screening with HIV testing and care TB screening during HIV care (Figure 1) is a high priority from multiple different perspectives, and the subject of recent comprehensive and systematic reviews. 18, 75 Screening newly diagnosed PLHIV targets a patient group with a high prevalence of undiagnosed TB disease, indications for IPT, high vulnerability to rapidly progressive TB with a fatal outcome and collective vulnerability to nosocomial transmission through a shared respiratory contact network at the HIV care clinic. Intensive TB screening with Xpert MTB/RIF and culture can increase pre-ART identification of TB patients dramatically, 30, 31, 39, 50, 78 leading to a low incidence of TB in the subsequent 12 months. Tests with pronounced prognostic signifi cance include detectable bacilli or antigen in urine or blood which identify individuals with high risk of early death. 39, 55 How best to integrate HIV testing and care into TB screening interventions delivered outside of HIV programmes is less well defi ned. At a minimum, it is essential to confi rm positive TB screening results and ensure that patients are promptly linked into TB care, with diagnostic HIV testing offered to all TB patients and participants with TB symptoms. As routine programmes lose about 15% of their newly diagnosed smear-positive TB patients and over 70% of newly diagnosed HIV-positive patients before any treatment is provided, care needs to be taken to avoid loss to follow-up between diagnosis and treatment. Loss to follow-up can be much higher when the diagnosis is made outside the routine setting, undermining the effectiveness of TB-HIV screening. 41 ART is by far the most effective method of preventing HIV-related TB, with a 65% reduction in incidence, rising to 84% if the CD4 count is <200 cells/mm. 11, 79 Irrespective of their fi nal diagnosis, people identifi ed as having symptoms of TB have a high probability of being HIV-infected, 22, 80 being unaware of their HIV status, being eligible for ART 80 and having a high risk of death if their HIV is not promptly diagnosed and treated. [80] [81] [82] [83] Indeed, in settings with generalised HIV epidemics, the NNTS to identify one patient with undiagnosed HIV is far lower than the NNTS to identify one patient with undiagnosed TB.
More completely integrated TB-HIV interventions include HIV treatment-as-prevention (TasP) strategies providing home-based HTC with TB screening and immediate ART and IPT for HIV-positive individuals, 84 and combined TB and household-based HIV and TB prevention. 6 ART for TasP has extremely high potential as a TB control strategy, with declining national and regional TB incidence apparent already just from routine ART scale-up. 84 Eight different trials of ART for HIV prevention that include TB outcomes are currently underway or planned. 85 
Follow-up of suspected tuberculosis
Once TB is suspected, no diagnostic test is able to both rule-in and rule-out TB accurately. 30, 86 As such, it is vital to ensure continuity of care by promptly diagnosing and treating HIV infection, and by provid-ing participants with follow-up management until TB is confi rmed or excluded. 80 As symptoms develop within a short time in patients with confi rmed 'subclinical' TB, repeated assessment after a short interval can distinguish progressive TB disease from falsepositive screening results. 56 In Harare, Zimbabwe, only 20% of smear-negative 'TB suspects' identifi ed in the community attended free follow-up care services. 87 Participants who attended follow-up had a high prevalence of undiagnosed HIV infection, a high rate of smear-negative TB diagnosis, and high mortality at 12 months during a period of very limited access to ART. 80
TUBERCULOSIS SCREENING USING DIFFERENT TUBERCULOSIS ENTRY POINTS
Community-based screening for tuberculosis regardless of symptoms (entry points 1 to 3)
Community-based TB screening has not been included in international recommendations for TB control for several decades. 88 Before the mid-1970s, radiological screening was widely implemented, but without clear demonstration of its impact on TB epidemiology or individual benefi t. 44, 88 Mobile radiography is still used in some European towns to screen high-risk groups such as the homeless and drug users, with acceptable NNTS and cost-effectiveness. 65, 69 The South African mining industry has used annual screening since the 1930s. The onset of the HIV epidemic was associated with decreasing proportions of TB in miners diagnosed using annual CXR screening. 67 TB found using screening had lower case fatality rates: an individually randomised trial of 6monthly vs. the standard of care 12-monthly CXR screening of 2634 gold miners led to a 52% reduction in the risk of death during the fi rst 2 months of anti-tuberculosis treatment in the more intensively screened arm. 8 Radiography in miners has much lower sensitivity for culture-confi rmed TB (~25%) than screening-naïve populations (>90%), potentially refl ecting 'screening escape'. 89 CXR screening is highly effi cient, and should be investigated in very high transmission settings, for example, combined with other intensifi ed TB-HIV activities in South African townships where the adult prevalence of culture-positive TB is up to 4% (NNTS ~25), and for outreach screening in prisons. Another obvious application would be in facility-based screening (Figure 1 ).
Outreach tuberculosis screening in general communities (entry points 2 and 3)
Outreach interventions in general communities also show promise. Here the aim is to provide access to diagnosis of symptomatic TB in the community. Studies in Zimbabwe and South Africa have shown high uptake, with 2-5% smear positivity prevalence in participants. 7, 41 Epidemiological impact was assessed in a cluster randomised trial, with 46 neighbourhoods in Harare, Zimbabwe (DETECTB) randomised to six rounds of 6-monthly active case fi nding using door-to-door enquiry for chronic cough in the household or mobile van with loudspeakers. 7 Participants provided sputum for smear microscopy results. Smear-positive TB case notifi cation rates increased substantially in both arms, with the mobile van arm diagnosing the most smear-positive TB. There was a substantial and highly signifi cant reduction in population-level culture-positive TB (before:after adjusted reduction of 41% over 2.5 years, from 7.9 per 1000 adult residents). An estimated 15-25% of undiagnosed smear-positive residents were diagnosed at each intervention round, 7,21 despite the intrinsic limitations of using a low sensitivity screening algorithm (chronic cough and microscopy 7 ) .
In contrast, a large cluster multifactorial randomised trial of 24 communities in Zambia and South A frica provided with 3 years of 1) enhanced case fi nding (ECF) in the community, and 2) household intervention, 22, 43 did not show any epidemiological benefi t from the ECF intervention despite consid erable participation. DETECTB and ZAMSTAR (Zambia South Africa TB and HIV Reduction) ECF were complex interventions with several differences: there was less focus on direct sputum collection in ZAMSTAR-ECF, and DETECTB included dedicated follow-up clinics for smear-negative patients and active tracing of smear-positive patients.
TB REACH, a case-fi nding initiative funded by the Canadian International Development Agency and coordinated by the WHO, is also providing numerous examples of highly successful TB screening interventions, 15, [90] [91] [92] [93] including a number of interventions using Xpert supported by UNITAID. So far the emphasis has been on increasing case detection, rather than follow-up, to show declining TB incidence trends.
Combined TB-HIV household contact tracing interventions (entry point 4)
Household contacts of TB patients are at high risk for undiagnosed TB, 40, 94 with two recent meta-analyses reporting a median yield of undiagnosed TB of 3.1% and 4.5%. 40, 94 Pronounced heterogeneity by region and screening algorithms was noted, with one recent study showing very high rates of subclinical culturepositive disease (Shapiro in Table 2 ). 24 According to conventional wisdom, intensive household contact tracing has limited potential to affect TB epidemiology, although of high individual benefi t, as only about 10% of TB patients report household TB exposure. 35 However, this has been challenged by a recent study (ZAMSTAR) that showed signifi cant (22%) reduction in undiagnosed culture-positive TB in the general community through a cluster randomised trial that combined TB screening, HIV testing and prevention counselling in Zambia and South Africa ('ZAMSTAR' Household Arm 6 ). The intervention was intensive, with three separate visits over the course of 12 months. Fitting of mathematical models to trial data suggests diffusion of indirect benefi ts beyond households directly covered by the intervention. 43 The major challenge of timely contact screening is the need for effi cient communications, transportation and a means of interacting with the community.
Broader facility-based tuberculosis screening (entry point 5)
Relatively few studies have assessed systematic screening of general out-patient clinic or primary care clinic attendees for TB in HIV-prevalent settings; 9 however, there are many reasons for prioritising intensifi ed screening for this entry point: fi rst, it is a natural extension of TB screening provided in HIV care settings, as general clinic attendees have high HIV prevalence and high rates of undiagnosed TB. 9 Second, it is an opportunity to strengthen provider-initiated HTC, 95 and numerous studies have shown poor identifi cation and management of people with TB symptoms in routine systems. Finally, screening all facility attendees for cough is already part of infection control policy. 96 A recent intervention in the low HIV prevalence country of Pakistan greatly increased case notifi cation rates using lay volunteers to provide outpatient screening, based around a mobile phone system for communication and payment of incentives. 97 Facility-based interventions have the potential for population-level impact if they are implemented well enough. The fi rst clear example of this was from Cape Town, South Africa, where a substantial fall in undiagnosed TB was reported for a community served by an unusually strong TB-HIV health clinic. 12
COSTS, COST-EFFECTIVENESS AND MATHEMATICAL MODELLING OF TUBERCULOSIS SCREENING INTERVENTIONS
An increasing number of studies are estimating full screening costs and the cost-effectiveness of TB screening. Costs per participant found to have TB are higher for TB screening than for patient-initiated diagnosis: for example, US$1117 per patient 41 in a South African community-based TB screening intervention and approximately US$809 under the various interventions funded through the TB REACH initiative. 15 However, these estimates do not include costs averted, for example, from managing patients found at an earlier stage of disease, nor from episodes of disease and death averted. Costs incurred through false-positive diagnoses also need to be included. Even relatively small per-patient costs will require substantial additional funding to be affordable by national TB control programmes in low-income countries. 98 Effective targeting to high TB prevalence risk groups and populations will be critical for maximising cost-effectiveness. 44 
KNOWLEDGE GAPS AND RESEARCH PRIORITIES IN TUBERCULOSIS SCREENING
Major gaps in our knowledge remain. For communitybased interventions, these gaps lie in some critical a reas. 44 It is still unclear to what extent TB screening can contribute to reduced TB transmission, and, if so, how intensively, how often and for how long TB screening interventions have to be delivered before appreciable gains are seen. 36, 99, 100 The nature and impact of critical health system constraints is also poorly d efi ned, as are individual risks and benefi ts from TB s screening, both for PLHIV and for HIV-negative participants.
Addressing our current knowledge gaps requires operational and public health research with appropriate impact evaluation, [101] [102] [103] and linked mathematical and economic modelling. Understanding the impact of screening on 'patient-important outcomes' such as survival and well-being, and population-level epidemiological impact are critical in guiding choices and investment. 44, 46, 104 Mathematical modelling can identify and clarify important key principles, identify misconceptions, constraints and theoretical limitations, as well as being a tool to guide realistic study design, cost-effectiveness and provide fuller analysis and projection of real-life data. 36, 84, 99, 100, 105 Among our most pressing needs are new diagnostics: a highly sensitive, portable, low-cost, point-ofcare diagnostic able to 'rule out' TB effectively would revolutionise TB screening at all levels of the health system and community and allow rapid scale-up of HIV testing. Furthermore, tools to enable effi cient population-level impact evaluation, such as robust and low-cost tests for recent TB infection able to evaluate transmission rates in communities and quantify facility-level infection control are desperately needed (Table 4) . 7, 22, 30, 31, 39, 43, 58, 78, 101, 103, 106 Evidence of impact on TB transmission is an ideal outcome, but difficult to measure and so not often evaluated in high TB incidence settings; results affected by HIV status One recent example used an incidence cohort design in schoolchildren 22, 43 TB prevalence in HIV-infected patients Assessed through repeated before-after design, regular surveillance with time trends, or cluster-randomised crosssectional outcomes New clinic attendees, or routine post-mortem
A key indicator of population-level TB control, and also the main target of prevention for TB-HIV interventions Occurs at high prevalence and clearly linked to TB transmission TB = tuberculosis; HIV = human immunodeficiency virus.
Without a TB equivalent for HIV-incidence assays, large cohorts, repeated cross-sectional measurements or analysis of time trends in TB incidence are required to measure trends in TB control (Table 4 ). These are not only expensive, but also often fail to deliver clear answers due to the logistical diffi culties of this kind of indirect evaluation. Demonstration projects providing high-intensity, high-coverage combined TB-HIV screening interventions could provide relatively rapid insight into which approaches to TB screening are most effective in very high TB incidence settings. Both facility-and community-based interventions need to be investigated for their acceptability and potential impact on the population, including settings with high MDR-TB rates. 84, 107 Intervention design should resist the temptation to over-emphasise sustainability and test low-intensity complex interventions without fi rst establishing effectiveness.
Without clear evidence to guide policy and practice, resources may be wasted on ineffective interventions, and, conversely, the value of effective interventions may be grossly under-estimated. The need to establish effectiveness is most pressing for communitywide interventions, where costs and potential harms, but also potential benefi ts, are at their highest, and where contemporary examples with impact evaluation have given confl icting results. 7, 43 Important operational questions include linkage and retention in TB-HIV care when screening individuals not already in chronic care services. Health systems research priorities include the feasibility of provider-initiated TB and HIV screening at the facility level, and models of delivering interventions through community-directed approaches. 96, 108, 109 
CONCLUSIONS
In high HIV prevalence settings with high rates of morbidity and mortality from TB, the evidence for pursuing much bolder TB screening policy and practice is compelling, despite high cost and many remaining unknowns. Facility-based TB screening and screening of household contacts should be greatly intensifi ed, while developing evidence around community-based interventions. As with HIV testing, a combination approach adapted to the local epidemiology will be needed. Gains from each TB infection averted are unusually high in the highly vulnerable HIV-infected members of the community, and the costs of TB screening are small compared to expenditure on HIV care.
Effective intervention with the limited diagnostics available today will have to start without clear evidence, but with investment in research to support impact evaluation, ideally at individual, clinic, facility and population level. More innovative approaches to defi ning and responding to needs include, for example, combined surveillance-response strategies used for targeting efforts against other major infectious diseases. 110 Geospatial and molecular epidemiology could allow us to capitalise on existing epidemiological, demographic, health service resource usage data. 111 Combined TB and HIV interventions are essential if any gains made through TB screening are to be maintained in high HIV prevalence settings, and they require joint planning, implementation and fi nancing from the early stages of planning. Effective linkage to treatment and prevention of both TB and HIV needs to be the focus of special attention for both TB and HIV screening. We cannot continue to tolerate high rates of undiagnosed TB in communities and health facilities, but need to act in proportion to the threat to health and wellbeing: the magnitude and consequences of XDR-TB and MDR-TB epidemics in South Africa provide a graphic illustration of the huge cost of failure to implement effective TB and HIV screening and care.
i En 20 années de taux d'incidence très élevés de la tuberculose (TB) et de forte mortalité TB dans les pays à haute prévalence de l'infection par le virus de l'immunodéficience humaine (VIH), les initiatives contre la TB sont très loin de correspondre à l'ampleur des réponses observées dans les programmes de malaria ou de VIH. En effet, les recommandations ont été focalisées de façon très étroite sur les personnes consultant les services de santé pour l'investigation des symptômes de TB ou les fréquentant pour des tests et des soins VIH. Toutefois, en dépit de l'investissement majeur récent et étendu des services TB et VIH, la TB non-diagnostiquée reste hautement prévalente au niveau de la collectivité, ce qui signifie que le diagnostic de la TB reste lent et incomplet.
Ceci maintient des taux élevés de transmission et expose les personnes atteintes par le VIH à des taux élevés de morbidité et de mortalité. Une utilisation plus intensive du dépistage de la TB avec des définitions plus larges des populations visées, des indications élargies du screening à la fois à l'intérieur et à l'extérieur des services de santé et une sélection ap-
propriée de nouveaux outils de diagnostic offrent la perspective d'une amélioration rapide de la lutte antituber-culeuse au niveau de la population. La précision du diagnostic des algorithmes adaptés (à débit élevé) reste une barrière majeure à l'égard de la réalisation de cet objectif.
Nous faisons ici la revue des évidences disponibles pour orienter une extension du dépistage de la TB dans les contextes où le VIH est prévalent, idéalement par des interventions combinées TB-VIH qui assurent le dépistage à la fois de la TB et du VIH et qui maximisent l'accès aux soins et à la prévention de la TB et du VIH.
Idéalement, nous devrions tester, traiter et prévenir la TB et la VIH de façon systématique et complète en offrant le dépistage à la fois de la TB et du VIH à tous les sujets fréquentant les services de santé, aux ménages TB et à tous les adultes dans les collectivités où le risque est le plus élevé. Toutefois, nous sommes toujours freinés par les techniques inadéquates en matière de diagnostic, par le financement et par la médiocrité de l'impact sur la population. Les recherches contemporaines pertinentes montrant l'importante nécessité, les avantages potentiels et les dangers d'un dépistage élargi et intensifié de la TB dans les contextes à prévalence élevée de VIH font l'objet des discussions de cette revue.
En 20 años de tasas de incidencia de tuberculosis (TB) exorbitantes y una gran mortalidad por esta causa en los países con alta prevalencia de infección por el virus de la inmunodeficiencia humana (VIH), las iniciativas emprendidas están muy lejos de corresponder en magnitud ni amplitud a las respuestas que se observan en los programas contra la malaria o la infección por el VIH. Por el contrario, las recomendaciones se han centrado en las personas que acuden a los centros de atención de salud por síntomas indicativos de TB o en busca de pruebas diagnósticas o atención de la infección por el VIH. Sin embargo, pese al reciente aumento de la inversión y a la ampliación de escala de los servicios que se ocupan de estas enfermedades, los casos de TB que se pasan por alto en la comunidad siguen siendo muy frecuentes, lo cual indica que el diagnóstico es aun demasiado lento e insuficiente. Esta situación favorece la persistencia de altos índices de transmisión y expone a las personas infectadas por el VIH a altas tasas de morbilidad y mortalidad.
Una intensificación de la detección sistemática de la TB con definiciones más amplias de las poblaciones destinatarias, indicaciones extendidas de ejecución en los centros sanitarios y por fuera de los mismos y una selección apropiada de nuevos instrumentos diagnósticos ofrece una perspectiva de mejoramiento rápido del control de la TB en la población. El principal freno al logro de esta meta sigue siendo la precisión diagnóstica de algoritmos adaptados (con alta productividad).
En el presente artículo se analizan los datos científicos existentes, con el propósito de orientar la ampliación de la detección sistemática de la TB en los entornos con alta prevalencia de infección por el VIH, idealmente mediante intervenciones combinadas contra la TB y el VIH que ofrezcan la detección de ambas enfermedades y fomenten al máximo la utilización de los servicios de atención y prevención. Lo ideal sería practicar las pruebas diagnósticas, tratar y prevenir la TB y la infección por el VIH de manera exhaustiva, por conducto de una oferta de detección conjunta, a todos los usuarios de los establecimientos de atención sanitaria en las comunidades que presentan el mayor riesgo de transmisión. Sin embargo, el progreso se ve obstaculizado por medios diagnósticos inadecuados, un financiamiento insuficiente y la escasez de datos sobre la repercusión en las poblaciones. En el presente análisis se examinan las investigaciones recientes pertinentes que han puesto de manifiesto la gran necesidad de evaluar de las posibles ventajas y los in convenientes de la ampliación y la intensificación de la detección de la TB en los entornos con alta prevalencia de infección por el VIH.
